Bristol-Myers Squibb (BMY) Receives a Buy from Guggenheim
I'm PortAI, I can summarize articles.
Guggenheim's Seamus Fernandez maintained a Buy rating on Bristol-Myers Squibb with a $62 price target. The stock closed at $54.66. Fernandez, a 5-star analyst, has a 29.8% average return. Bristol-Myers also received a Buy from Bank of America Securities, while Bernstein rated it Hold. Fernandez covers the Healthcare sector, including Eli Lilly & Co and Cidara Therapeutics.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments